Subscribe to Search results

Some evidence has held that doctors during the 1970s, 1980s and 1990s were part of a medical regime centred around a more paternalistic paradigm. However, alternate evidence offered to the inquiry have held that regardless of the time period, there are certain fundamental ethical norms and principles which lie at the heart of the medical profession including autonomy, beneficence and non-maleficence.

Published on:

Evidence presented to the inquiry held that while most doctors took the view that not discussing the risks associated with blood products with patients would not result in deterring patients from using the various treatments anyway. However, Professors Farsides and Kerridge on the medical experts panel to the inquiry disagreed, stating until one has disclosed all the risks to a patient, then one cannot assume patients are making a fully informed decision.

Published on:

Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to explain the risks of treatment to patients.

Published on:

Speakers from the Medical Ethics Experts Panel held that it was ethically wrong not to promptly provide patients with the outcomes of their diagnosis and test results.

Published on:

In Edinburgh the principal product used in 1976 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1977 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1978 was cryoprecipitate.

Published on:

In Edinburgh the principal product used in 1979 was cryoprecipitate.

Published on:

From 1980, when Professor Ludlam arrived in Edinburgh, the volume of NHS concentrates used exceeded the volume of cryoprecipitate for the first time.

Published on:

In 1974 - 1975, at the Glasgow Royal Infirmary while commercial concentrates were in use cryoprecipitate was the predominant product.

Published on:

During the 1980, the haemophilia centre at the Royal Hospital for Sick Children ("RHSC") in Yorkhill, Glasgow, provided haemophilia treatment to children from the Glasgow area and across the West of Scotland. 55 had Haemophilia A, 14 had Haemophilia B and 1 had von Willebrand disease.

Published on:

The annual return taken from Glasgow in 1976, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1977, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1978, held that the use of concentrates (more NHS than commercial, although Profilate, Factorate, Koate and Hemofil were all used) exceeded the use of cryoprecipitate.

Published on:

The annual return taken from Glasgow in 1979 saw a reduction in the use of cryoprecipitate and an increase in the use of concentrates, both NHS and (in particular) commercial

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes stated that the majority of discussions taking place around 1975 were centred around the types of donors used to give plasma in commercial centres.

Published on:

Evidence presented to the Penrose Inquiry by Dr Forbes held that the risk of dying due to a bleed outweighed the possible downside of using factor concentrates.

Published on:

Dr Forbes agrees with a letter written by Dr John Cash on 24 January 1976, with held that that the importation of Factor VIII concentrates was "bringing with it a potentially lethal virus into the whole community" in reference to hepatitis.

Published on:

During 1978, before the complications had become apparent, Dr Forbes described the recent move to home treatment as highly valuable for patients.

Published on:

By 1976 Factor 9 concentrate was the dominant treatment with comparatively little use of fresh frozen plasma. The 1976 annual returns recorded that 396 patients were treated with a total of 5,561,834 Factor 9 units in the UK. The average per patient was 18,790 units. 60 patients were on home treatment.

Published on: